$30.59
Tarsus Pharmaceuticals is a biotechnology business based in the US. Tarsus Pharmaceuticals shares (TARS) are listed on the NASDAQ and all prices are listed in US Dollars. Tarsus Pharmaceuticals employs 244 staff and has a trailing 12-month revenue of around $83.4 million.
Our top picks for where to buy Tarsus Pharmaceuticals Inc stock
How to buy Tarsus Pharmaceuticals stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – TARS. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Tarsus Pharmaceuticals stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Tarsus Pharmaceuticals stock price (NASDAQ: TARS)
Use our graph to track the performance of TARS stocks over time.Tarsus Pharmaceuticals shares at a glance
Latest market close | $30.59 |
---|---|
52-week range | $12.57 - $42.50 |
50-day moving average | $26.41 |
200-day moving average | $28.28 |
Wall St. target price | $58.50 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-4.46 |
Is it a good time to buy Tarsus Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Tarsus Pharmaceuticals price performance over time
Historical closes compared with the close of $30.59 from 2024-09-06
1 week (2024-08-30) | 12.84% |
---|---|
1 month (2024-08-07) | 34.82% |
3 months (2024-06-07) | -5.00% |
6 months (2024-03-07) | -13.83% |
1 year (2023-09-07) | 97.35% |
---|---|
2 years (2022-09-07) | 94.59% |
3 years (2021-09-07) | 19.68% |
5 years (2019-09-03) | N/A |
Tarsus Pharmaceuticals financials
Revenue TTM | $83.4 million |
---|---|
Gross profit TTM | $-17,763,000 |
Return on assets TTM | -34.55% |
Return on equity TTM | -75.04% |
Profit margin | -180% |
Book value | $6.63 |
Market Capitalization | $1 billion |
TTM: trailing 12 months
Tarsus Pharmaceuticals share dividends
We're not expecting Tarsus Pharmaceuticals to pay a dividend over the next 12 months.
Tarsus Pharmaceuticals share price volatility
Over the last 12 months, Tarsus Pharmaceuticals's shares have ranged in value from as little as $12.57 up to $42.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tarsus Pharmaceuticals's is 1.058. This would suggest that Tarsus Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
To put Tarsus Pharmaceuticals's beta into context you can compare it against those of similar companies.
- Kala Pharmaceuticals (KALA.US): -2.041
- Kodiak Sciences (KOD.US): 2.336
- Regenxbio (RGNX.US): 1.218
Tarsus Pharmaceuticals overview
Tarsus Pharmaceuticals, Inc. , a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Frequently asked questions
What percentage of Tarsus Pharmaceuticals is owned by insiders or institutions?Currently 8.769% of Tarsus Pharmaceuticals shares are held by insiders and 111.218% by institutions. How many people work for Tarsus Pharmaceuticals?
Latest data suggests 244 work at Tarsus Pharmaceuticals. When does the fiscal year end for Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals's fiscal year ends in December. Where is Tarsus Pharmaceuticals based?
Tarsus Pharmaceuticals's address is: 15440 Laguna Canyon Road, Irvine, CA, United States, 92618 What is Tarsus Pharmaceuticals's ISIN number?
Tarsus Pharmaceuticals's international securities identification number is: US87650L1035
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question